Neurotrophic factors and Parkinson's disease: the emergence of a new player?
The administration of neurotrophic factors is a potential approach to the therapy of neurodegenerative disorders such as Parkinson's disease. However, issues relating to compound delivery and potential side effects have limited the clinical application of this treatment strategy. The identification of CDNF and MANF, which constitute a new class of neurotrophic factors active against dopaminergic neurons, may provide new hope for therapeutic approaches to neurodegenerative disorders based on neurotrophic factors or downstream components of their signaling pathways.
Dauer
William
W
Departments of Neurology and Pharmacology, Columbia University, Neurological Institute of New York, Box 204, 710 West 168th Street, New York, NY 10032, USA. wtd3@columbia.edu
D000818:Animals; D004298:Dopamine / Q000502:physiology; D006801:Humans; D009414:Nerve Growth Factors / Q000502:physiology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
D009414:Nerve Growth Factors; D004298:Dopamine